Therapies for Psoriatic Nail Disease. A Systematic Review

Overview

Journal J Rheumatol

Specialty Rheumatology

Date 2006 May 26

PMID 16724366

Citations 17

Authors

Sarah Cassell

Arthur F Kavanaugh

Affiliations

Soon will be listed here.

Abstract

Nail involvement is common in patients with psoriasis and psoriatic arthritis, affecting 80%-90% of patients at some time. It also has significant effects on quality of life. Psoriatic nail disease can be refractory to treatment, and different features may respond variably to different therapies. The lack of standardized outcome assessments hinders the interpretation of available data. In this systematic evidence-based review of the literature, we assess various treatments for psoriatic nail disease.

Citing Articles

Efficacy of Biologics Targeting Tumour Necrosis Factor-alpha, Interleukin-17 -12/23, -23 and Small Molecules Targeting JAK and PDE4 in the Treatment of Nail Psoriasis: A Network Meta-analysis.

Szebenyi J, Gede N, Hegyi P, Szakacs Z, Solymar M, Eross B Acta Derm Venereol. 2020; 100(18):adv00318.

PMID: 32965504 PMC: 9309877. DOI: 10.2340/00015555-3640.

Optimal management of nail disease in patients with psoriasis.

Piraccini B, Starace M Psoriasis (Auckl). 2018; 5:25-33.

PMID: 29387579 PMC: 5683109. DOI: 10.2147/PTT.S55338.

Nail psoriasis: the journey so far.

Dogra A, Arora A Indian J Dermatol. 2014; 59(4):319-33.

PMID: 25071247 PMC: 4103264. DOI: 10.4103/0019-5154.135470.

Interventions for nail psoriasis.

de Vries A, Bogaards N, Hooft L, Velema M, Pasch M, Lebwohl M Cochrane Database Syst Rev. 2013; (1):CD007633.

PMID: 23440816 PMC: 11611064. DOI: 10.1002/14651858.CD007633.pub2.

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1.

Strober B, Cather J, Cohen D, Crowley J, Gordon K, Gottlieb A Dermatol Ther (Heidelb). 2012; 2(1):1.

PMID: 23205324 PMC: 3510391. DOI: 10.1007/s13555-012-0001-y.